Celgene 1Q net income slips on marketing costs
SUMMIT, N.J. (AP) — Celgene's net income fell 4 percent in the first quarter as marketing costs increased following the marketing approval of two drugs. The Food and Drug Administration broadened the approval of Celgene's drug Abraxane during the …
See all stories on this topic »
Personal Branding Guide | Marketing Yourself To Employers
Do you know what your personal brand is? Are you aware of the importance of having a strong, unique and diverse personal brand? Here is how to define one.WISH
See all stories on this topic »
Business Marketing Association Expands Global Presence
The latest chapter is part of the organization's objective to provide business-to-business (B2B) marketing professionals around the world with the resources and support to enhance their practices and expand their careers. Beginning immediately, BMA …
See all stories on this topic »
Popular Questions
Why did Celgene’s first-quarter net income slip because of marketing costs?
Celgene’s first-quarter net income declined as higher marketing costs reduced the amount left after operating expenses. The added spending likely reflected efforts to promote its medicines and support commercial activity. Investors should compare marketing expenses with revenue growth to assess whether the investment is producing sufficient returns.
How did marketing expenses affect Celgene’s 1Q earnings?
Marketing expenses put pressure on Celgene’s 1Q earnings by increasing costs faster than net income could absorb them. This means the company’s financial performance cannot be judged from revenue alone. Reviewing operating expenses alongside sales and profit figures helps clarify the impact of the marketing campaign.
Did Celgene’s first-quarter results show a problem with its business?
The report that Celgene’s 1Q net income slipped on marketing costs does not by itself prove that the business was weakening. A decline in profit may result from deliberate spending intended to expand product awareness or future sales. Investors should examine revenue trends, product performance, and whether marketing costs remain elevated in later quarters.
What should investors watch after Celgene’s 1Q net income slipped on marketing costs?
Investors should watch whether Celgene’s marketing spending leads to stronger revenue and improved profitability in subsequent quarters. They should also track operating expenses, net income, and management’s explanation for the increased costs. Sustained expense growth without corresponding sales gains would place additional pressure on earnings.